This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Steinlechner, B. Articles by Rajek, A. Search for Related Content PubMed PubMed Citation Articles by Steinlechner, B. Articles by Rajek, A. Related Collections Heart Pain Pharmacology

---

CARDIOVASCULAR ANESTHESIA

Postoperative Analgesia with Remifentanil in Patients Undergoing Cardiac Surgery

Division of Cardiothoracic and Vascular Anesthesia and Intensive Care Medicine, University Hospital of Vienna, Austria

Address correspondence to Barbara Steinlechner, MD, Cardiothoracic and Vascular Anesthesia and Intensive Care Medicine, University Hospital Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria. Address e-mail to barbara.steinlechner{at}univie.ac.at.

Remifentanil, a short-acting opioid, is commonly used in cardiac anesthesia. In this study we sought to demonstrate the feasibility of pain treatment and to determine the remifentanil dose necessary for adequate analgesia in tracheally extubated patients after cardiac surgery. Thirty patients undergoing elective cardiac surgery were included in this study. After surgery, the intraoperatively administered remifentanil was initially continued at 0.05 µg · kg^–1 · min^–1. Before tracheal extubation, a nonsteroidal antiinflammatory drug was administered and remifentanil was reduced to 0.035 µg · kg^–1 · min^–1. Pain assessment using a visual analog scale (VAS) was performed after tracheal extubation, in 2-min intervals for 10 min, every 10 min until the end of the first hour and every 30 min during the ensuing 5 h. A VAS score 30 or a respiratory rate <10 breaths/min was followed by an increase or decrease in the remifentanil dose by 0.005 µg · kg^–1 · min^–1, respectively. For rapid dose adaptation during the first 10 min, remifentanil was increased twice by 0.005 µg · kg^–1 · min^–1 and then 3 times by 0.01 µg · kg^–1 · min^–1. With a mean remifentanil dose of 0.051 µg · kg^–1 · min^–1 VAS decreased to 26 ± 14 after 30 min. Sufficient analgesia was achieved with remifentanil doses ranging from 0.03 to 0.09 µg · kg^–1 · min^–1. A maximum mean remifentanil dose of 0.057 µg · kg^–1 · min^–1 was reached after 4 h. The combination of remifentanil with a nonsteroidal antiinflammatory drug provided adequate analgesia in 73% of patients 30 min after tracheal extubation. Rapid dose titration was necessary during the first 10 min in 50% of patients. Increasing the initial remifentanil dose could shorten the titration period but may be associated with respiratory complications.

This article has been cited by other articles:

				B. Steinlechner, M. Dworschak, B. Birkenberg, T. Lang, A. Schiferer, A. Moritz, B. Mora, and A. Rajek Low-dose remifentanil to suppress haemodynamic responses to noxious stimuli in cardiac surgery: a dose-finding study Br. J. Anaesth., May 1, 2007; 98(5): 598 - 603. [Abstract] [Full Text] [PDF]

				B. Steinlechner, M. Dworschak, B. Birkenberg, G. Grubhofer, M. Weigl, A. Schiferer, T. Lang, and A. Rajek Magnesium moderately decreases remifentanil dosage required for pain management after cardiac surgery Br. J. Anaesth., April 1, 2006; 96(4): 444 - 449. [Abstract] [Full Text] [PDF]